BioCanRx Pre-Event Workshop
BioCanRx, in partnership with CellCAN, presents…
Working with Patients to Inform Early-phase Cancer Clinical Trial Design
Date: Wednesday, 8 March 2017
Time: 1:00 - 4:00 PM EST
Location: Westin Montreal, Montreal, Quebec
This workshop will outline what patient-oriented research is, how it is used to inform and impact clinical trials currently, how BioCanRx intends to conduct patient-oriented research to inform cancer clinical trial design, and provide ways for patients to get involved.
Specifically, BioCanRx network investigators will highlight how they will engage patients to inform early-phase clinical trial design of the first Made-in- Canada CAR-T therapy.
- Manoj Lalu, BioCanRx Network Investigator
- Justin Presseau, BioCanRx Network Investigator
- Anne Lyddiatt, Patient on SPOR National Steering Committee
- Zarah Monfaredi, Ottawa SPOR Program Facilitator
By the end of this workshop, attendees will learn...
- The importance of patient-oriented research and how it is done
- The facilitators, barriers and preferences for implementation of trials
- How evidence-informed clinical trial designs are developed
- How patients have engaged in research in the past
- How patients will be engaged in the first Made-in-Canada CAR-T early-phase clinical trial
Who Should Attend
- Patients and caregivers
- Other members of the public
- Research trainees
- Non-government organizations focused on cancer research and representing cancer patients
How to Register to this FREE workshop
Registration is now closed. For information, contact Jovian Tsang.
About BioCanRx: Biotherapeutics for Cancer Treatment
BioCanRx’s vision is to cure patients and enhance the quality of life of those living with cancer. We will do this by supporting world-class research in the area of biotherapeutics for cancer treatment, and by accelerating to the clinic the most promising cancer biotherapeutics designed to save lives and enable a better quality of life. The Network consists of 42 founding investigators, 260 highly qualified personnel, 5 core facilities that specialize in GMP viral vectors and GLP immune-monitoring, and 43 partners in the academic, industrial and charity sectors. Through an innovative, collaborative funding process, which has funded 30 exciting projects to date, BioCanRx is becoming a world-leader in the translation, manufacture and adoption of innovative cancer biotherapeutics for the benefit of all cancer patients.
Learn more about BioCanRx at www.biocanrx.com